🔎 Trials Near Me

Akèy › Maladi Crohn › Utah

Etid klinik pou Maladi Crohn nan Utah

8 etid pou Maladi Crohn ap chèche patisipan nan sit nan Utah.

Vil nan Utah

Tèks ofisyèl etid la (Anglè)

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Care Access - Ogden /ID# 266428, Ogden
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • University of Utah, Salt Lake City
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Velocity Clinical Research, Salt Lake City-Site Number: 8400147, West Jordan
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • Care Access Research - Ogden, Ogden
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Utah Health, Salt Lake City
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  • University of Utah Health, Salt Lake City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05230173

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

  • Investigational Site Number: 8400016, Ogden
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Mar 27, 2026 · NCT06958536

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.